Crizanlizumab

Identification

Name

Crizanlizumab

Accession Number

DB15271

Description

Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.⁹ Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels.⁸

Currently, patients are prescribed hydroxyurea to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality.⁴ Though hydroxyurea has been shown to reduce the frequency of vaso-occlusive crises, adherence to this therapy is difficult due to adverse effects and the high variability of response to the drug between patients.⁵ Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. It was developed by Novartis and was granted FDA approval on November 15, 2019.⁹

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Protein Chemical Formula

Not Available

Protein Average Weight

146000.0 Da (Theoretical)

Sequences

Not Available

Synonyms

• crizanlizumab-tmca

External IDs

• SEG101

Pharmacology

Indication

Crizanlizumab is indicated to reduce the frequency of vaso-occlusive crisis in patients with sickle cell diseases who are ≥16 years old.⁹

Associated Conditions

• Vaso-occlusive Crisis

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Crizanlizumab is a P-selectin inhibitor that prevents interactions between endothelial cells, platelets, red blood cells, and leukocytes.⁹ It has a long duration of action as it is given every 4 weeks.⁹ Patients should be counselled regarding the risk of infusion reactions as well as crizanlizumab's interference with platelet counts using EDTA tubes.⁹

Mechanism of action

Crizanlizumab binds to P-selectin on endothelial cells and platelets, preventing their interaction with P-selectin glycoprotein ligand 1 on endothelial cells, platelets, red blood cells, and leukocytes.^6,9 By preventing this interaction, components of the blood are less likely to come together, causing a vaso-occlusive crisis in patients with sickle cell diseases.^6,9 The median per year incidence of vaso-occlusive crises was 1.04 in the high-dose crizanlizumab group, 2.00 in the low-dose crizanlizumab group, and 2.08 in the placebo group.³

Target	Actions	Organism
AP-selectin	inhibitor	Humans

Absorption

Crizanlizumab reaches a C_max of 0.16mg/mL with an AUC of 34.6mg*hr/mL.⁹

Volume of distribution

The volume of distribution of crizanlizumab is 4.26L.⁹

Protein binding

Monoclonal antibodies are generally not protein bound^1,2.

Metabolism

Crizanlizumab is expected to be metabolized into smaller peptides and amino acids.⁹

Route of elimination

Monoclonal antibodies are eventually phagocytosed and broken down to smaller peptides and amino acids which are eliminated in a similar fashion to other proteins.^1,2 Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.⁷

Half-life

Given a 5mg/kg dose of crizanlizumab, the mean terminal elimination half life of crizanlizumab is 10.6 days in healthy subjects and 7.6 days in patients with sickle cell disease.⁹

Clearance

Given a 5mg/kg dose of crizanlizumab, the clearance rate is 11.7ml/hr in healthy subjects.⁹

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Data regarding the toxicity of crizanlizumab is not readily available.⁹

Affected organisms

• Humans

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

No interactions found.

Products

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Adakveo	Injection	10 mg/1mL	Intravenous	Novartis Pharmaceuticals Corporation	2019-11-15	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Categories

ATC Codes

B06AX01 — Crizanlizumab

• B06AX — Other hematological agents
• B06A — OTHER HEMATOLOGICAL AGENTS
• B06 — OTHER HEMATOLOGICAL AGENTS
• B — BLOOD AND BLOOD FORMING ORGANS

Drug Categories

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Blood and Blood Forming Organs
• Immunoglobulin G
• Immunoglobulins
• Serum Globulins

Chemical TaxonomyProvided by Classyfire

Description

Not Available

Kingdom

Organic Compounds

Super Class

Organic Acids

Class

Carboxylic Acids and Derivatives

Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent

Peptides

Alternative Parents

Not Available

Substituents

Not Available

Molecular Framework

Not Available

External Descriptors

Not Available

Chemical Identifiers

UNII

L7451S9126

CAS number

1690318-25-2

References

General References

1. Tabrizi MA, Tseng CM, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X. [PubMed:16478695]
2. Lobo ED, Hansen RJ, Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 Nov;93(11):2645-68. doi: 10.1002/jps.20178. [PubMed:15389672]
3. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP: Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. [PubMed:27959701]
4. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51. doi: 10.1001/jama.289.13.1645. [PubMed:12672732]
5. Riley TR, Riley TT: Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date. J Blood Med. 2019 Aug 30;10:307-311. doi: 10.2147/JBM.S191423. eCollection 2019. [PubMed:31507334]
6. Gardner RV: Sickle Cell Disease: Advances in Treatment. Ochsner J. 2018 Winter;18(4):377-389. doi: 10.31486/toj.18.0076. [PubMed:30559624]
7. Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29. [PubMed:28653357]
8. Ankit Mangla; Moavia Ehsan; Smita Maruvada (2019). Sickle Cell Anemia. Stat Pearls.
9. FDA Approved Drug Products: Adakveo Crizanlizumab-TMCA Intravenous Injection [Link]

External Links

RxNav

2262421

Wikipedia

Crizanlizumab

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Recruiting	Treatment	Sickle Cell Disease (SCD)	1
2	Active Not Recruiting	Treatment	Sickle Cell Disease (SCD)	1
2	Recruiting	Treatment	Novel Coronavirus Infectious Disease (COVID-19)	1
2	Recruiting	Treatment	Priapism	1
2	Recruiting	Treatment	Sickle Cell Disease (SCD)	2
1, 2	Recruiting	Treatment	Agnogenic Myeloid Metaplasia	1
Not Available	Available	Not Available	Sickle Cell Disease (SCD)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection	Intravenous	10 mg/1mL

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on May 20, 2019 09:06 / Updated on June 12, 2020 11:42